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Background: Aberrant methylation of CpG sites served as an epigenetic marker for
building diagnostic, prognostic, and recurrencemodels for hepatocellular carcinoma (HCC).
Methods: Using Illumina 450K and EPIC Beadchip, we identified 34 CpG sites in
peripheral blood mononuclear cell (PBMC) DNA that were differentially methylated in
early HCC versus HBV-related liver diseases (HBVLD). We employed multiplex bisulfite
sequencing (MBS) based on next-generation sequencing (NGS) to measure methylation
of 34 CpG sites in PBMC DNA from 654 patients that were divided into a training set (n =
442) and a test set (n = 212). Using the training set, we selected and built a six-CpG-
scorer (namely, cg14171514, cg07721852, cg05166871, cg18087306, cg05213896,
and cg18772205), applying least absolute shrinkage and selection operator (LASSO)
regression. We performed multivariable analyses of four candidate risk predictors (namely,
six-CpG-scorer, age, sex, and AFP level), using 20 times imputation of missing data, non-
linearly transformed, and backwards feature selection with logistic regression. The final
model’s regression coefficients were calculated according to “Rubin’s Rules”. The
diagnostic accuracy of the model was internally validated with a 10,000 bootstrap
validation dataset and then applied to the test set for validation.
Results: The area under the receiver operating characteristic curve (AUROC) of the model
was 0.81 (95%CI, 0.77–0.85) and it showed good calibration and decision curve analysis.
Using enhanced bootstrap validation, adjusted C-statistics and adjusted Brier score were
0.809 and 0.199, respectively. The model also showed an AUROC value of 0.84 (95% CI
0.79–0.88) of diagnosis for early HCC in the test set.October 2021 | Volume 11 | Article 7563261
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Frontiers in Oncology | www.frontiersin.orgConclusions: Our model based on the six-CpG-scorer was a reliable diagnosis tool for
early HCC from HBVLD. The usage of the MBS method can realize large-scale detection
of CpG sites in clinical diagnosis of early HCC and benefit the majority of patients.Keywords: multiplex bisulfite sequencing, CpG methylation, early HCC, diagnostic model, enhanced
bootstrap validationINTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary
liver tumor with high morbidity and mortality. It has been
estimated that hepatitis B virus (HBV) infection causes 50%–
80% of HCC cases worldwide (1). The progression of multi-stage
hepatocarcinogenesis from chronic HBV infection (CHB) to
HBV-related liver cirrhosis (LC) and finally to HBV-related
HCC is complex. There is 2%–7% incidence of LC per year in
CHB patients (2), and 2%–4% annual incidence of HCC in LC
patients (3). Meanwhile, CHB patients can also develop HCC
without cirrhosis. The new data show that annual HCC rates
ranged 0.03%–1.57% among non-LC Asian CHB male patients
(4). In involving 34,952 patients, the study suggested that 2.29% of
CHB patients would develop HCC despite hepatitis B surface
antigen (HBsAg) seroclearance (5). There are several mechanisms
related with HBV-related hepatocarcinogenesis progression
including viral regulatory HBV × protein interrupting liver cell
proliferation and increasing HBV replication (6), integration of
HBV DNA into the host cell genome provoking host cell
chromosomal alterations and insertional mutagenesis of cancer
genes (7), and host genomic and epigenetic aberrant variation
induced by inflammation (8).
The high mortality rate of HCC is mostly due to its discovery
at advanced stages. There is an urgent unmet need for
biomarkers that can detect early HCC development in CHB
and LC liver background. DNA methylation profiles for early
stage of HCC in peripheral blood mononuclear cells (PBMC) are
different from healthy controls as well as CHB. HCC has a
specific DNA methylation signature in easily accessible PBMC
and can serve as “noninvasive” biomarkers for detection of early
HCC as well as HCC progression (9). Several studies have
demonstrated CpG methylation prepared for constructing
diagnostic, prognostic, and recurrence models for HCC (10–12).
However, in these models, measurement methylation of CpGs
was performed by pyrosequencing or methylation specific PCR.
These methods were laborious and involved fussy work (13) for
detection methylation of dozens of CpGs and inevitable increase
of inter-batch differences in large samples. This could cause
adverse effects on the diagnostic efficacy of the model.
Therefore, in this study, we applied multiplex bisulfite
sequencing (MBS), which is based on the next-generation
sequencing (NGS) method to assess the methylation status of
34 CpGs in 654 samples at the same time. Multivariable methods
identified a minimal set of CpGs to achieve optimal prediction.
Meanwhile, we handled multiple imputation to complete missing
data and bootstrapped training datasets for backward feature
selection. The model incorporated both the six-CpG-scorer2
methylation panel and demographic and clinical characteristics
risk factors for early diagnosis onset of HCC from HBV-related
liver disease (HBVLD) including CHB and LC.MATERIALS AND METHODS
Data Processing for CpG Selection
The raw IDAT files of Illumina 450K Beadchip data including
CHB patients (n = 10) and Barcelona clinic liver cancer staging
system (BCLC) 0 (n = 10), BCLC-A (n = 10), BCLC-B (n = 10),
and BCLC-C (n = 9) were obtained from Gene Expression
Omnibus (accession number: GSE67170) (9), which was
prepared to obtain differentially methylated CpGs between CHB
and each HCC stage. Forty-four paired PBMC samples were taken
from 22 patients before and again after diagnosis of HCC. The 22
patients were diagnosed as LC prior to HCC, and then 5 were
diagnosed as HCC BCLC-0 and 17 were BCLC-A. Twenty-two LC
and 22 early HCC PBMC samples were subjected to genome-wide
DNA methylation assay by using Illumina EPIC Beadchip (data
did not published). The R package ChAMP was applied for
methylation raw data processing and the paired t tests were used
to analyze the differentially methylated CpGs between LC and
HCC BCLC-0 and -A. The differentially methylated CpGs with
|delta beta|≥ 0.2 and remaining significant after Bonferroni-
corrected p value < 0.05 were selected.
Patient Study Population
The cross-sectional retrospective study, using the convenient
sampling method, was conducted from August 2010 to July 2019
at Beijing You’An Hospital, which is an infectious diseases
specialist tertiary hospital in China. A total of 654 patients
were included in this study. The demographic and clinical
characteristic data of patients with CHB, LC, and early HCC
were collected from hospital electronic medical records. The
inclusion criterion of CHB was that hepatitis B surface antigen
(HBsAg) seropositive status lasted at 6 months or beyond
according to the Asia-Pacific clinical practice guidelines on the
management of hepatitis B: a 2015 update (14). Diagnosis of
hepatitis B-related LC was based on a combination of clinical,
laboratory, imaging features, and liver biopsies according to the
guideline of prevention and treatment for chronic hepatitis B
(2010 Version). Diagnosis of HCC was based on the radiological/
histological criteria according to 2012 EASL clinical practice
guidelines: Management of chronic hepatitis B virus infection,
Barcelona clinic liver cancer staging system (BCLC) (15).
Exclusion criteria were as follows: less than 18 years old; co-
infection with human immunodeficiency virus, hepatitis C virus,October 2021 | Volume 11 | Article 756326
Li et al. CpGs Diagnosis eHCC Using MBSor hepatitis D virus; coexistence of liver injury caused by drug
intake, alcohol consumption, and autoimmune hepatitis;
pregnancy; and lactation. The study was approved by the
Institutional Ethics Committee of the Beijing You’An Hospital.
All participants signed written informed consent on enrolment.
DNA Bisulfite Converted and Multiplex
Bisulfite Sequencing
After extraction, PBMC DNA bisulfite was converted with
sodium bisulfite according to the protocol of EZ DNA
Methylation-Direct Kit (ZYMO Research, Irvine, USA), whose
bisulfite conversion rate was >99.5%. Bisulfite-transformed DNA
was a single strand and we measured the concentration of the
single-strand DNA using a Qubit 2.0 (Thermo, USA, catalog
Q10212) to ensure that adequate amounts of single-template
DNA were invested for library construction. A panel contained
34 “CpG-free” primer pairs designed to target all candidate
CpGs. Library preparation was performed by nest-PCR. First-
round PCR reaction was set up as follows: bisulfite converted
DNA 5 ml; forward primer mix (10 mM) 1 ml; reverse primer mix
(10 mM) 1 ml; 2×PCR Ready Mix 15 ml (total 25 ml) (KAPA HiFi
HotStart ReadyMix PCR). The plate was sealed and PCR was
performed in a thermal instrument (BIO-RAD, T100TM) using
the following program: 1 cycle of denaturing at 98°C for 3 min,
then 27 cycles of denaturing at 98°C for 20 s, annealing at 60°C
for 4 min, and final elongation at 72°C for 2 min. Finally, hold at
10°C. The PCR products were checked using electrophoresis in
1% (w/v) agarose gels in TBE buffer (Tris, boric acid, EDTA)
stained with ethidium bromide (EB) and visualized under UV
light. Then, we used AMPure XP beads to purify the amplicon
product. After that, the second-round PCR was performed. PCR
reaction was set up as follows: first-round PCR amplicon product
(10 ng/ml) 2 ml; universal P7 primer with barcode (10 mM) 1 ml;
universal P5 primer with barcode (10 mM) 1 ml; 2×PCR Ready
Mix 15 ml (total 30 ml) (Kapa HiFi Ready Mix). The plate was
sealed and PCR was performed in a thermal instrument (BIO-
RAD, T100TM) using the following program: 1 cycle of
denaturing at 98°C for 1 min, then eight cycles of denaturing
at 98°C for 20 s, annealing at 60°C for 20 s, elongation at 72°C for
30 s, and a final extension at 72°C for 2 min. Then, we used
AMPure XP beads to purify the second-round PCR amplicon
product. The libraries were then quantified and pooled. Paired-
end sequencing of the library was performed on the HiSeq XTen
sequencers (Illumina, San Diego, CA).
Data QC and SNP Calling
MBS raw data were processed by Sangon Biotech. Briefly, raw
reads were filtered according to three steps: (a) removing adaptor
sequence if reads contains by cutadapt (v 1.2.1); (b) removing
low quality bases from reads 3’ to 5’ (Q < 20) by PRINSEQ-lite
(v 0.20.3); (c) Bismark (version v0.22.1) (www.bioinformatics.
babraham.ac.uk/projects/) was used for CpGs detected with
default parameters.
CpG Selection and Assessment
A multi-CpG-based scorer was constructed to diagnose the early
HCC patients from HBVLD in the training dataset. The leastFrontiers in Oncology | www.frontiersin.org 3absolute shrinkage and selection operator (LASSO) with cross-
validation method was applied to select the most significant CpGs
from the 34described inSupplementaryTable S1. The processwas
mainly performed using the “glmnet” package (16) based on the R
software (Version 4.0.3) and depicted in Figure 1A.
Statistical Analysis
Firstly, the restricted cubic splines (RCS) were applied to detect the
possible nonlinear dependency of the relationship between early
HCC and 17 continuous variables, using three knots at the 25th,
50th, and 75th percentiles of the corresponding variable. There
were potential threshold associations between early HCC and five
indices [age, direct bilirubin (DBil), total protein (TP), albumin
(ALB), and hemoglobin] (p-value for nonlinear < 0.001). We have
categorized age to the following groups:<43 years and ≥43 years,
DBil to <7 mmol/L and ≥7 mmol/L, TP to <65 g/L and ≥65 g/L,
ALB to <42 g/L and ≥42 g/L, and hemoglobin to <140 g/L and
≥140 g/L based on the RCS curve. The other four indices [total
bilirubin (TBil), g-glutamyltranspeptidase (g-GT), platelet count
(PLT), and lymphocyte count (LYM)] were categorized to normal
and abnormal groups based on the medical reference value,
respectively. The other seven indices [alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), white blood cell count (WBC), monocyte count (MONO),
neutrophil count (NUET), and alpha-fetoprotein (AFP)] were log-
transformed, respectively (Supplementary Table S1).
Missing values in original dataset were imputed 20 times
using imputation with predictive mean matching (“mice”
package) (17). For each of the 20 complete dataset, 500
bootstrapping datasets were generated, and backwards feature
selection with the Akaike Information Criterion (AIC) was
performed on the 10,000 datasets (“rms”) (18). Second-order
interaction terms were also tested for inclusion. The selected
predictors constructed the final model, whose regression
coefficients were calculated using “psfmi” package according to
“Rubin’s Rules” (19, 20). The enhanced bootstrap method was to
evaluate the stability of the diagnosis model. Discrimination
ability was assessed by the area under the receiver operating
characteristic curve (AUROC) and C-statistics. Calibration was
applied for assessment of agreement between predicted and
observed risks across of the population. The nomogram
presented the results of the modeling process. Decision curve
analysis (DCA) was performed to determine the model clinical
usefulness. The construction process referred to this report (21)
and the model analysis conforms to the reporting standards of
STARD (22) and was depicted in Figure 1B.RESULTS
Demographic and Characteristics
of the Patients
After a strict pathological diagnosis and exclusion process, 168
patients with CHB, 173 patients with liver cirrhosis, 148 patients
withHCCBCLC-0 stage, and165patientswithHCCBCLC-Astage
were collected in Beijing You’An hospital and included into this
study (Figure 1A). A total of 654 patients were randomly assignedOctober 2021 | Volume 11 | Article 756326
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FIGURE 1 | Study design and analysis protocol. (A) Study design and flow diagram. A total of 654 PBMC samples were prospectively collected. Thirty-four CpGs
were investigated using multiplex bisulfite sequencing in 341 HBVLD (CHB: 168, LC: 173) and 313 early HCC group (BCLC-0:148, BCLC-A: 165). The least absolute
shrinkage and selection operator method (LASSO) cross-validation was introduced to selected six CpGs and built a six-CpG-scorer in the training dataset (n = 442,
212 early HCC and 230 HBVLD). (B) Schematic representation of statistical analysis. The analyses were performed on 18 selected predictors measured on 442
parents involved in the training set. Twenty complete datasets were created after 20 times missing imputation, and 17 candidate variables were detected the
possible nonlinear dependency of the relationship with early HCC, of which 7 variables were transformed in a non-linear fashion. Resampling 500 times were from
each of the 20 complete datasets, leading to a total number of 10,000 bootstrap datasets. A backward feature selection with AIC was repeated on each of the
10,000 bootstrap datasets for selecting the most relevant risk variables for early HCC. The factors chosen at least once during the feature selection procedure
constituted the final mode, whose coefficients were estimated using Rubin’s Rule from the 20 complete datasets. In internal validation, the model predictiveness and
correcting overfit were assessed using 10,000 separate enhanced bootstrapped datasets. The nomogram presented the final mode. Decision curve analysis and
clinical impact curves were performed to determine the final model clinical usefulness. The final mode also showed an obvious diagnosis potential in test set (n =
212, 101 early HCC and 111 HBVLD). HBVLD, HBV-related liver disease; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer staging system.Frontiers in Oncology | www.frontiersin.org October 2021 | Volume 11 | Article 7563264
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clinical characteristics of patients are shown in Table 1.
CpG Selection and Panel Signature
Building for Early HCC Diagnosis
On the basis of our previous studies (9), we portrayed
differentially methylated CpGs between CHB and each of theFrontiers in Oncology | www.frontiersin.org 5HCC phases utilizing Limma package with Bonferroni
correction. The number of specifically methylated CpGs
between CHB and each of the HCC phases included 2,285 for
BCLC-0; 2,233 for BCLC-A; 3,345 for BCLC-B; and 23,596 for
BCLC-C. There were 326 differentially methylated CpGs that
could specifically distinguish early HCC (BCLC-0 and BCLC-A
stages) from CHB (Figure 2A). Moreover, 20 robust CpGTABLE 1 | Clinical characteristics of the enrolled participants in this study (n = 654).
Training set (442) Test set (212)
HBVLD (n = 230) Early HCC (n = 212) HBVLD (n = 111) Early HCC (n = 101)
Age (years, mean ± SD) 45.37 ± 11.9 46.22 ± 11.7 45.38 ± 12.08 52.24 ± 10.36
Sex (M/F) 170/60 174/38 80/31 90/11
ALT (U/L)
<40 108 (47.0%) 128 (60.4%) 51 (45.9%) 60 (59.4%)
≥40 121 (52.6%) 83 (39.2%) 60 (54.1%) 41 (40.6%)
AST (U/L)
<40 125 (54.3%) 140 (66.0%) 59 (53.2%) 55 (54.5%)
≥40 104 (45.2%) 71 (30.9%) 52 (46.8%) 46 (44.5%)
Total bilirubin (mmol/L)
<21 144 (62.6%) 147 (69.3%) 79 (71.1%) 63 (62.4%)
≥21 85 (37.0%) 64 (30.2%) 32 (18.9%) 38 (37.6%)
Direct bilirubin (mmol/L)
<7 169 (73.5%) 175 (82.5%) 88 (79.3%) 72 (71.3%)
≥7 60 (26.1%) 36 (17.0%) 23 (20.7%) 29 (28.7%)
Total protein (g/L)
<65 168 (73.4%) 135 (59.0%) 85 (76.6%) 65 (64.4%)
≥65 61 (26.5%) 76 (35.8%) 26 (23.4%) 36 (35.6%)
Albumin (g/L)
<40 136 (59.1%) 105 (49.5%) 72 (64.9%) 45 (44.6%)
≥40 93 (40.4%) 106 (50.0%) 39 (35.1%) 56 (55.4%)
g-GT (U/L)
<45 121 (52.6%) 95 (44.8%) 52 (46.8%) 40 (39.6%)
≥45 96 (41.7%) 95 (44.8%) 52 (46.8%) 61 (60.4%)
Alkaline phosphatase (U/L)
≤100 172 (74.8%) 142 (67.0%) 83 (74.8%) 48 (47.5%)
>100 46 (20.0%) 48 (22.6%) 22 (19.8%) 37 (36.6%)
WBC count × 109/L
<3.5 174 (75.7%) 157 (74.1%) 79 (71.2%) 74 (73.3%)
3.5–9.5 46 (20.0%) 42 (19.8%) 24 (21.6%) 14 (13.9%)
>9.5 10 (4.3%) 12 (5.7%) 8 (7.2%) 13 (12.9%)
Hemoglobin (g/L)
<130 143 (62.2%) 138 (65.1%) 77 (69.4%) 60 (59.4%)
≥130 87 (37.8%) 73 (34.4%) 34 (30.6%) 41 (40.6%)
Platelet count × 109/L
<125 129 (56.1%) 108 (50.9%) 70 (63.1%) 58 (57.4%)
≥125 101 (43.9%) 104 (49.1%) 41 (36.9%) 43 (42.6%)
Lymphocyte count × 109/L
<1.1 172 (74.8%) 149 (70.3%) 85 (76.6%) 58 (57.4%)
≥1.1 58 (25.2%) 62 (29.2%) 26 (23.4%) 43 (42.6%)
Monocyte count × 109/L
<0.6 214 (93.1%) 182 (85.8%) 107 (96.4%) 81 (80.2%)
≥0.6 16 (6.9%) 29 (13.7%) 4 (3.6%) 20 (19.8%)
Neutrophil count × 109/L
<1.8 166 (72.2%) 167 (78.8%) 80 (72.1%) 71 (70.3%)
1.8–6.3 53 (23.0%) 17 (8.0%) 26 (23.4%) 12 (11.9%)
>6.3 11 (4.8%) 17 (8.0%) 5 (4.5%) 18 (17.8%)
Alpha-fetoprotein (ng/ml)
<20 178 (77.4%) 110 (51.9%) 86 (77.5%) 41 (40.6%)
≥20 50 (21.7%) 96 (45.3%) 25 (22.5%) 58 (57.4%)October 2021 | VolumHBVLD, HBV-related liver disease; CHB, chronic hepatitis B; LC, HBV-related liver cirrhosis; HCC, hepatocellular carcinoma; BCLC, Barcelona clinic liver cancer staging system; g-GT,
g-glutamyltranspeptidase; WBC, white blood cell. ALT, alanine aminotransferase; AST, aspartate aminotransferase.e 11 | Article 756326
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CpGs (|delta beta |≥0.2). Meanwhile, 36 differentially
methylated CpGs (|delta beta |≥0.2) could specifically
distinguish early HCC from LC using paired t tests with
Bonferroni correction, and 17 CpGs were selected for this
study (unpublished work). In all, methylation ratios of 34
CpGs (three CpGs overlap) were investigated using MBS in
the HBVLD and early HCC samples (Supplementary Tables
S2, S3).
Thirty-four CpGs were reduced to six potential predictors
using the LASSO regression model. The cross-validated error
plot and a coefficient profile plot of the LASSO regression model
were produced (Figures 2B, C). The logistic regression was usedFrontiers in Oncology | www.frontiersin.org 6for building the six-CpG-scorer: where risk score = −0.87 – 3.73 ×
cg14171514 + 2.58 × cg07721852 + 6.91 × cg05166871 − 9.85×
cg18087306 + 4.50 × cg05213896 + 4.39 × cg18772205, where
values of each CpG were methylation ratio measured from MBS.
We then applied this formula to calculate the risk score for early
HCC of each patient based on their individual six CpG
methylation ratio. The risk score was significantly increased in
the early HCC samples versus the HBVLD samples (p < 2.22 ×
10−16) (Figure 2D). The six CpGs and their combination
six-CpG-scorer also showed diagnostic accuracy (Figure 2E
and Supplementary Table S4). According to determining of
maximum Youden index, 0 severed as the optimal cutoff point




FIGURE 2 | Construction of the six-CpG-scorer in training set. (A) Venn diagram of the overlap between differentially methylated CpGs between different HCC
BCLC stages (0-C) and CHB. (B) Fivefold CV LASSO coefficients of 34 candidate CpGs. The first black vertical dotted line corresponds to the lmin that minimized
binomial deviance during CV. The second black vertical dotted line corresponds to l1se, used for the selection of six biomarker CpGs. (C) LASSO coefficient profile
of the 34 early HCC-associated CpGs. A vertical line was drawn at the value chosen by fivefold cross-validation. (D) The six-CpG-scorer of each participant from the
liver disease, early HCC group in the training dataset was calculated, and the score was significantly increased in the early HCC versus the HBV-related liver disease
(HBVLD) samples (Wilcoxon rank sum test was used to compare six-CpG risk score between two groups). (E) Area under the receiver operating characteristic curve
(AUROC) of the six-CpG-scorer and its component CpGs. Data were AUROC (95% CI). HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer
staging system; LASSO, least absolute shrinkage and selection operator method.October 2021 | Volume 11 | Article 756326
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risk group. The distribution of demographic and clinical
characteristics did not vary significantly between the high-risk
and low-risk group (Supplementary Table S5).Six-CpG-Scorer Signature Was
Independent of Clinical Factors
The univariate logistic analysis was performed in 10,000
bootstrap datasets. Six of the 18 candidate variables indicated a
higher early HCC risk; among these were higher age (≥43 years),
male, individuals with higher AFP, higher six-CpG-scorer, lower
TP (<65 g/L), and lower TBil (Table 2).
Four variables were selected by the backward feature selection
procedure in 10,000 bootstrap datasets (Table 2). Age, sex, AFP,
and six-CpG-scorer signature were independent risk factors for
early HCC. The six-CpG-scorer also showed significantly higher
predictive accuracy than AFP (Supplementary Table S6) and
other demographic and clinical risk factors.Development of an Individualized Early
HCC Diagnosis Nomogram
The early HCC diagnosis model incorporated the four risk
predictors and estimated on the 20 complete datasets according
to Rubin’s Rule. The prognostic index X (based on logistic
regression model coefficients) was: X = −1.0944708 – 0.7183741 ×
Sex (Male= 0, Female=1)+1.7286974×Age [(<43 years) = 0, (≥ 43
years) = 1)] + 0.2761166 × lg(AFP) + 0.7902764 × six-CpG-scorer.
The calculation of the predicted risk of early HCC from HBVLD
was as follows: risk of eHCC = 11+exp (−X). It presented as the early
HCC nomogram (eHCC nomogram) (Figure 3A).Frontiers in Oncology | www.frontiersin.org 7Estimation for the C-Statistics and Brier
Score by Bootstrap Validation
Internal validation was performed using the 500 times
resampling enhanced bootstrap method from each of the 20
complete datasets. The result showed negligible model optimism.
The apparent C-statistics and apparent Brier score was 0.805 and
0.200, respectively. The optimism of the C-statistics and Brier
score was −0.0042 and 0.00164, respectively. The adjusted C-
statistics and Brier score was 0.809 and 0.199, respectively.
Diagnostic Performance and Clinical
Usefulness of eHCC Nomogram
The AUROC of the model was 0.81 (95% CI, 0.77–0.85) in the
training set. The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) when used in
differentiating the early HCC from HBVLD were 70.0%, 77.8%,
74.4%, and 73.6%, respectively. The calibration curve of the eHCC
nomogram for the probability of early HCC demonstrated good
agreement between prediction and observation in the training set
(Figure 3B). The decision curve analysis of the eHCC nomogram
and that for the model without the six-CpG-scorer is presented in
Figure 3C. The DCA showed that if the threshold probability of a
patient or doctor was >10%, using eHCC nomogram to predict
early HCC adds more benefit than either the treat-all-patients
scheme or the treat-none scheme (Figure 3D).
Diagnostic Performance of the eHCC
Nomogram in the Test Set
We further enrolled 212 patients including 111 HBVLD and 101
early HCC to serve as the test set for validation of the diagnostic
potential. The risk score was significantly increased in the early
HCC versus the HBVLD group in the test set (p = 2.7×10–7)TABLE 2 | All 18 variables included in the backwards feature selection analysis.
Variable Univariable Multivariable
OR (95% CI) p-value OR (95% CI) p-value
Age (years), ≥43 vs. <43 5.07 (3.07–8.56) 1.75e–07*** 5.23 (3.24–8.63) 2.56e-08***
Sex (Female vs. Male) 0.32 (0.17–0.56) 0.0011** 0.32 (0.19–0.53) 0.000248***
Alpha-fetoprotein (AFP) (ng/ml), log10
a 1.50 (1.35–1.69) 1.85e–09*** 1.48 (1.34–1.64) 3.05e-10***
Six-CpG-Scorer 2.37(1.83 –3.12) 1.10e–07*** 2.58 (2.01–3.36) 1.08e-09***
Total protein(g/L), ≥65 vs. <65 0.38 (0.19–0.71) 0.01209* 0.32 (0.20–0.51) 0.56
Total bilirubin(mmol/L), ≥21 vs. <21 0.32 (0.14–0.69) 0.01588* 0.45 (0.32–0.64) 0.78
AST (U/L), log10 0.77 (0.45–1.28) 0.40551
ALT (U/L), log10 0.51(0.43–1.06) 0.15320
Direct bilirubin (mmol/L), ≥7 vs. <7 0.55 (0.77–2.35) 0.38832
g-GT (U/L), ≥45 vs. <45 1.15 (0.83–1.61) 0.47649
Albumin (g/L), ≥40 vs. <40 0.74 (0.41–1.36) 0.42147
Alkaline phosphatase (U/L), log10 0.77 (0.44–1.35) 0.44623
Hemoglobin (g/L), ≥115 vs. <115 1.68 (0.91–3.14) 0.16827
White blood cell count × 109/L, log10 0.84 (0.17–4.24) 0.85430
Monocyte count × 109/L, truncate_99 + log10
b 2.29 (1.14–4.67) 0.05410.
Platelet count × 109/L, ≥125 vs. <125 0.84(0.50–1.42) 0.58796
Lymphocyte count × 109/L, ≥1.1 vs. <1.1 0.82 (0.46–1.49) 0.58026
Neutrophil count× 109/L, log10 1.08 (0.37–2.86) 0.89871October 2021 | Volume 11 | AraNonlinear transformation.
bMonocyte count variable was truncated with 1st and 99th percentiles and then performed with nonlinear transformation.
OR, odds ratio; g-GT, g-glutamyltranspeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Signif. codes: “***” 0.001, “**” 0.01, “*” 0.05.ticle 756326
Li et al. CpGs Diagnosis eHCC Using MBS(Figure 4A). The eHCC nomogram achieved an AUROC value of
0.84 (95% CI 0.79–0.88) between the early HCC and HBVLD
(Figure 4B). The calibration curve demonstrated good agreement
between prediction and observation in early HCC (Figure 4C). The
sensitivity, specificity, PPV, and NPV were used in differentiating
the early HCC from HBVLD and were 68.9%, 82.9%, 80.0%, and
71.8%, respectively. The nomogram also indicated good clinical
benefits in DCA, which suggested an obvious diagnosis efficacy for
early HCC from HBVLD (Figure 4D).DISCUSSION
The identification of differentially methylated CpG genome-wide
from the Methylation Chip (450K and EPIC) often required a
test and/or replication in extra cohorts. The pyrosequencing,
bisulfite-conversion-based methylation PCR, PCR cloning, and
Sanger sequencing method were laborious and involved fussy
work for detection methylation of each CpG site and inevitable
increase of inter-batch differences in large samples. The deep
sequencing of specific target CpGs often called for MBS, which isFrontiers in Oncology | www.frontiersin.org 8based on the NGS method to assess the methylation status at
target DNA regions and with very high coverage (13). The
important and commendable characteristics of MBS were low
cost, low DNA input, and high repeatability and scalability. In
addition, the MBS was compatible with common NGS platforms
using standard equipment, making it available to most
laboratories (23). Construction of amplicon libraries according
to a target CpG panel was a key step of MBS. In multiplex PCR
using bisulfite converted DNA as template, mixed-base primers,
whose pyrimidine base Y contains a “mixture” of cytosines and
thymines at the cytosine site and whose purine base R contains a
mixture of guanines and adenines at the guanine site, greatly
affected the amplification efficiency and led to a decrease in
library quality. In the design of this study, we applied 34 “CpG-
free” primer pairs (i.e., primers that do not bind to a region
containing CpG dinucleotides) targeting each region covering
candidate CpGs, which had been considered to produce “non-
preferential” amplification of bisulfite-converted DNA genome
(24). We successfully establish a version of the “CpG-free”
primer pair panel applied in MBS to simultaneously investigate
the methylation status of 34 candidate CpGs across a large
sample size (n = 654). The complete and accurate methylationA B
D
C
FIGURE 3 | Performance evaluation and clinical usefulness of the eHCC nomogram. (A) Nomogram was based on age, sex, alpha-fetoprotein (AFP), and the
six-CpG-scorer. (B) Calibration curves of the eHCC nomogram in the training dataset. The x-axis represented the predicted probability of early HCC risk from
nomogram. The y-axis represented the actual early HCC rate. The blue diagonal dotted line represented a perfect performance by an ideal nomogram. The red
dotted line represented the performance of the eHCC nomogram; the green solid line represented bootstrap-corrected performance of eHCC nomogram. (C) Area
under the receiver operating characteristic curve (AUROC) of eHCC nomogram in training dataset. Data were AUROC (95% CI). (D) Decision curve analysis (DCA) of
the nomogram predicted early HCC in the training set. The x-axis indicated the threshold probability and the y-axis indicated the net benefit. The blue curve
represented the eHCC nomogram. The red line indicated the assumption that all patients were early HCC. The horizontal green line indicated the assumption that
there were early HCC. eHCC, early hepatocellular carcinoma.October 2021 | Volume 11 | Article 756326
Li et al. CpGs Diagnosis eHCC Using MBSdata of 34 candidate CpGs allowed us to screen out and integrate
into a six-CpG-scorer with application of LASSO regression.
CpG methylation served as an apparatus focused on non-
invasive biomarkers for chronic diseases {age-related diabetes
(25), diabetic embryopathy (26), coronary heart disease (27),
nonalcoholic fatty liver disease (28), or cancer [bladder cancer
(29), rectal cancer (30), and HCC (31)]} and had been set up by
compelling studies. Our recent study looked at CpG methylation
alterations of HBV-related liver disease and developed a model
discriminating compensated cirrhosis patients from CHB and
decompensated cirrhosis ones based on two CpG biomarkers
(32). Our previous study also supported the feasibility of using
350 CpGs for detection of each stages of HCC fromhealthy control
(9). In this study, we successfully established and validated a novel
diagnostic nomogram based on the six-CpG-scorer to distinguish
early HCC patients from CHB and LC ones. Furthermore, this
proposed six-CpG-scorer can diagnose the early HCC better than
other demographic and characteristics risk factors. Meanwhile,
eHCC nomogram validated considerable diagnostic potential to
early HCC and indicated good clinical benefits in DCA.
The CpGs serving as independent risk factors of HCC from
mining analysis of Methylation Chip data might point out a novel
trace for the exploration ofHCCprogressmechanism. Based on theFrontiers in Oncology | www.frontiersin.org 9Illumina Human Beadchip 27K array, sphingomyelin
phosphodiesterase 3 (SMPD3) and neurofilament, heavy
polypeptide (NEFH) were found to behave as tumor suppressor
genes inHCCafter validation invitroand invivo (33).Gentilini et al.
applied theMethylation450KBeadChiparrayand showed that four
epigenetically regulated candidate genes [adherens junctions
associated protein 1 (AJAP1), adenosine deaminase RNA specific
B2 (ADARB2), protein tyrosine phosphatase receptor type N2
(PTPRN2), and sidekick cell adhesion molecule 1 (SDK1)] were
potentially involved in thepathogenesis ofHCC(34).Thefindingof
AJAP1 was consistent with clinical observation of low AJAP1
expression as an independent factor for predicting disease-free
survival (DFS) (35). Mechanically, AJAP1 could block epithelial-
to-mesenchymal transition (EMT) via suppressing b-catenin/zinc
finger E-box binding homeobox 1 (ZEB1) signaling.
In this study, cg14171514 was located within the 5’UTR of the
neuroblast differentiation-associated protein (AHNAK) gene,
and significantly hypomethylated both in the PBMC DNA of
early HCC patients compared with HBVLD ones in this study.
Consistently, the aberrant hypomethylation status in the
AHNAK gene promoter region from HCC patients’ PBMC
DNA was verified in methylation-specific PCR (MSP) results
of our previous studies (36). Aberrant AHNAKmethylation levelA B
DC
FIGURE 4 | Diagnostic performance of the eHCC nomogram in the test set. (A) The risk score was significantly increased in the early HCC samples versus the
HBVLD group (p = 2.7×10–7). (B) Area under the receiver operating characteristic curve (AUROC) of eHCC nomogram in the test set. Data were AUROC (95% CI).
(C) Calibration curves of the eHCC nomogram in the test set. The x-axis represented the predicted probability of HCC risk from nomogram. The y-axis represented
the actual HCC rate. The blue diagonal dotted line represented a perfect performance by an ideal nomogram. The red dotted line represented the performance
of the eHCC nomogram, and the green solid line represented bootstrap-corrected performance of eHCC nomogram. (D) Decision curve analysis (DCA) of the
nomogram predicted early HCC in the test set. The x-axis indicated the threshold probability, and the y-axis indicated the net benefit. The blue curve represented the
eHCC nomogram. The red line indicated the assumption that all patients were HCC. The horizontal green line indicated the assumption that there were early HCC.
eHCC, early hepatocellular carcinoma.October 2021 | Volume 11 | Article 756326
Li et al. CpGs Diagnosis eHCC Using MBSin PBMC DNA was associated with HCC. In addition, AHNAK
mRNA had been reported to be overexpressed in liver cancer
tissues by qPCR (36) and the cancer genome atlas (TCGA) data
(Supplementary Figure S1). Our novel results from
immunoprecipitation in combination with mass spectrometry
(IP-MS) analysis strongly indicated that AHNAK protein was
involved in and promoted HCC progress (data not published).
The cg18087306 was located within the body of Lamin B2
(LMNB2) gene, whose expression level in HCC tissue was
higher relative to peritumor tissue. LMNB2 was a promising
HCC prognostic and diagnostic biomarker (37).CONCLUSIONS
We had shown characteristic changes of 34 CpGs in HBVLD and
early HCC across a clinical cohort, identified the six-CpG-scorer,
and validated their diagnostic efficacy. Thus, we proposed that
the six-CpG-scorer-based nomogram is a potential non-invasive
diagnostic tool for early HCC from HBVLD, and performed
internal validation using the 500 times resampling enhanced
bootstrap method from each of the 20 complete datasets to
evaluate the stability and then applied it to the test set for
validation. The external validation of the monogram will be
needed in much larger cohorts from different centers or regions
to promote the efficacy and stability to further benefit
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